Cervical Cancer: Open Access
Open Access

Anal cancer; Screening protocols; High-risk groups; Human Papillomavirus (HPV); Immunocompromised; Early detection

Introduction

Anal cancer is a relatively rare but serious malignancy affecting the tissues of the anus, primarily linked to HPV infection. High-risk groups, including men who have sex with men (MSM), individuals with weakened immune systems, and those with a history of HPVrelated conditions, face elevated susceptibility. Early detection through effective screening protocols is crucial for improving outcomes and reducing mortality rates. This article provides an overview of current screening recommendations tailored for high-risk populations, emphasizing the importance of anal cancer awareness and the role of timely intervention in mitigating the impact of this disease [1].

Anal cancer, though less common than other forms of cancer, can significantly impact individuals, especially those in high-risk groups. Screening protocols aimed at early detection play a crucial role in improving outcomes and saving lives. This article explores the importance of anal cancer awareness and the protocols recommended for high-risk populations [2].

Understanding anal cancer

Anal cancer develops in the tissues of the anus, which is the opening at the end of the digestive tract through which stool leaves the body. Most anal cancers are squamous cell carcinomas, arising from the squamous cells lining the anus. The Human Papillomavirus (HPV) infection is a significant risk factor for anal cancer, particularly strains HPV-16 and HPV-18 [3].

High-risk groups

Certain individuals are at higher risk of developing anal cancer:

Individuals with weakened immune systems: Such as those living with HIV/AIDS or those who have undergone organ transplantation.

History of genital warts: Caused by HPV infection, which can increase the risk of anal cancer.

Smokers: Tobacco use can increase the risk of anal cancer.

Importance of screening

Early detection through screening is crucial for improving outcomes in anal cancer. Screening aims to detect precancerous changes or early-stage cancers before symptoms develop, allowing for timely intervention and treatment.

Screening protocols

The following are key screening protocols recommended for highrisk groups:

Digital rectal examination (DRE): A healthcare provider examines the anus and rectum for abnormalities, such as lumps or growths. While not a standalone screening test, it can prompt further evaluation if abnormalities are found [4].

High-resolution anoscopy (HRA): This procedure involves using a special magnifying instrument called an anoscope to examine the anus and lower rectum more closely. It allows for visualization of any suspicious areas that may require biopsy.

Anal pap smear (Anal Cytology): Similar to a cervical Pap smear, this test collects cells from the anus to detect abnormalities or precancerous changes. It is especially useful in detecting HPV-related changes.

HPV testing: HPV testing may be recommended, particularly for high-risk populations, to identify the presence of HPV strains associated with anal cancer [5].

Screening guidelines

The Centers for Disease Control and Prevention (CDC) recommends annual anal Pap smears for sexually active MSM, starting at age 21 or at the onset of sexual activity.

HIV-positive individuals: Guidelines often recommend more frequent screening, such as anal Pap smears every 6 months, due to their increased risk.

Others at increased risk: Screening protocols may vary based on individual risk factors and medical history. Consultation with a healthcare provider can determine the appropriate screening schedule [6].

Challenges and Considerations

Despite the importance of screening, challenges exist in implementing widespread anal cancer screening programs. These include lack of awareness among healthcare providers and patients, as well as the discomfort some individuals may feel discussing anal health.

Discussion

Anal cancer, though relatively uncommon compared to other cancers, poses a significant health risk, especially among high-risk groups characterized by factors such as Human Papillomavirus (HPV) infection, compromised immune systems, and specific sexual behaviors. Effective screening protocols tailored to these populations are critical for early detection, which can substantially improve treatment outcomes and survival rates [7].

Screening for anal cancer aims to identify precancerous changes or early-stage cancers before symptoms appear. This early detection is crucial because symptoms like rectal bleeding, pain, or changes in bowel habits often indicate advanced disease, making treatment more challenging.

MSM are disproportionately affected by anal cancer due to higher rates of HPV infection, particularly high-risk strains like HPV-16 and HPV-18. The virus can persist in the anal canal, leading to cellular changes that may progress to cancer if undetected [8].

Those with weakened immune systems, such as individuals living with HIV/AIDS or recipients of organ transplants who take immunosuppressive drugs, are at increased risk. Their compromised ability to control HPV infections heightens the likelihood of developing anal cancer.

Individuals with a history of genital warts or other HPV-related diseases have an elevated risk of anal cancer. HPV, known for its role in cervical cancer, similarly affects the anus when persistent infections lead to cellular abnormalities.

Recommended screening protocols

A basic yet important part of screening, DRE allows healthcare providers to physically assess the rectum and anus for abnormalities such as lumps or masses. It serves as an initial step to prompt further evaluation if suspicious findings are noted [9].

HRA involves using a magnifying instrument to closely examine the anus and lower rectum for abnormal tissues. This procedure enables visualization of potentially precancerous lesions that may not be visible to the naked eye.

Similar to the Pap smear used for cervical cancer screening, anal cytology collects cells from the anal canal to detect abnormal changes indicative of precancerous or cancerous conditions. It is particularly useful for detecting HPV-related abnormalities.

HPV testing may be recommended, especially for high-risk populations, to detect the presence of high-risk HPV strains associated with anal cancer. This can inform healthcare providers about the risk level and guide further management.

Despite the clear benefits of screening, several challenges exist. These include the stigma associated with discussing anal health, lack of awareness among both healthcare providers and high-risk individuals, and the need for specialized training in performing and interpreting screening tests like HRA and anal cytology [10].

Conclusion

Screening protocols for anal cancer aim to detect precancerous changes or early-stage cancers in high-risk populations, such as MSM and those with weakened immune systems. Early detection through regular screening can lead to timely intervention and improved outcomes. It is essential for healthcare providers to educate patients about anal cancer risk factors and the importance of screening, ultimately contributing to better health outcomes and increased awareness within high-risk communities.

References

1. Yadav P (2015) Health Product Supply Chains in Developing Countries : Diagnosis of the Root Causes of Underperformance and an Agenda for Reform Health Product Supply Chains in Developing Countries : Diagnosis of the Root Causes of Underperformance and an Agenda for Refo. Health Syst Reform 1: 142-154.

Indexed at, Google Scholar, Crossref

2. Lemma M (2018) Analysis Of Challenges In The Private Sector Pharmaceutical Import And Distribution Channel In Ethiopia.

Google Scholar                    

3. Strong S, Delzell P, Trygstad W, Fitzpatrick G, Haley-hyer P (2020) The Impact of COVID-19 on the Pharmaceutical Supply Chain.

Google Scholar                    

4. Mcdonnell A, Pisani E, Mcdonnell A (2021) A Path to Resiliency : Mitigating the Impacts of COVID-19 on Essential Medicines Supply Chains.

Google Scholar                    

5. Ayati N, Parisa S, Shekoufeh N (2020) Short and long term impacts of COVID-19 on the pharmaceutical sector. Daru 28: 799-805.

Indexed at, Google Scholar, Crossref

6. EFDA. Temporary COVID-19 Medical Product Approval and Import Permit Authorization Directive.
7. Uwizeyimana T, Hashim HT, Kabakambira JD, Mujyarugamba JC, Dushime J, et al. (2021) Drug supply situation in Rwanda during COVID 19 : issues , efforts and challenges. J Pharm Policy Pract.

Google Scholar

8. Health G (2020) Medical Product Quality Report – COVID-19 Issues. Med Qual Res Gr ,University OXFORD.

Google Scholar                    

9. Miller FA, Young SB, Dobrow M, Shojania KG (2021) Vulnerability of the medical product supply chain: The wake-up call of COVID-19. BMJ Qual Saf. 30: 331-5.

Indexed at, Google Scholar, Crossref

10. Yimenu DK, Demeke CA, Kasahun AE, Siraj EA, Wendalem AY, et al. (2021) Impact of COVID-19 on Pharmaceutical Care Services and the Role of Community Pharmacists: A Multi-Center Cross-Sectional Study in Ethiopia. SAGE Open Nurs.

Indexed at, Google Scholar, Crossref